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Abstract
Proteins that discriminate between cisplatin–DNA adducts and oxaliplatin–DNA adducts are
thought to be responsible for the differences in tumor range, toxicity, and mutagenicity of these
two important chemotherapeutic agents. However, the structural basis for differential protein
recognition of these adducts has not been determined and could be important for the design of
more effective platinum anticancer agents. We have determined high-resolution NMR structures
for cisplatin–GG and undamaged DNA dodecamers in the AGGC sequence context and have
compared these structures with the oxaliplatin–GG structure in the same sequence context
determined previously in our laboratory. This structural study allows the first direct comparison of
cisplatin–GG DNA and oxaliplatin–GG DNA solution structures referenced to undamaged DNA
in the same sequence context. Non-hydrogen atom rmsds of 0.81 and 1.21 were determined for the
15 lowest-energy structures for cisplatin–GG DNA and undamaged DNA, respectively, indicating
good structural convergence. The theoretical NOESY spectra obtained by back-calculation from
the final average structures showed excellent agreement with the experimental data, indicating that
the final structures are consistent with the NMR data. Several significant conformational
differences were observed between the cisplatin–GG adduct and the oxaliplatin–GG adduct,
including buckle at the 5′ G6•C19 base pair, opening at the 3′ G7•C18 base pair, twist at the
A5G6•T20C19 base pair step, slide, twist, and roll at the G6G7•C19C18 base pair step, slide at the
G7C8•C18G17 base pair step, G6G7 dihedral angle, and overall bend angle. We hypothesize that
these conformational differences may be related to the ability of various DNA repair proteins,
DNA binding proteins, and DNA polymerases to discriminate between cisplatin–GG and
oxaliplatin–GG adducts.
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Cisplatin [CP, cis-diamminedichloroplatinum(II)] and carboplatin [CBDCA, cis-
diammine-1,1-cyclobutanedicarboxylatoplatinum(II)] are widely used for treatment of
testicular cancer, ovarian cancer, head and neck tumors, and a variety of other solid tumors.
However, many tumors are intrinsically resistant or develop acquired resistance to these
chemotherapeutic agents, and tumors that are resistant to one of these platinum compounds
are usually cross-resistant to the other. The mutagenicity of CP in vivo (1) is also of concern
because secondary malignancies have been associated with CP chemotherapy (2).
Considerable effort has been spent to develop third-generation platinum anticancer agents
that would not share these limitations. Oxaliplatin [OX, trans-(R,R)-1,2-
diaminocyclohexaneoxalatoplatinum(II)] is one such compound and has recently been
approved for the treatment of colorectal cancer and tumors that are resistant to CP and
CBDCA. While OX does exhibit some mutagenicity (3), it appears to be less mutagenic than
CP (4). CP and CBDCA form Pt–DNA adducts that contain the cis-diammine carrier
ligands, while OX forms Pt–DNA adducts that contain the trans-(R,R)-1,2-
diaminocyclohexane carrier ligand. For the sake of simplicity, we will refer to these as CP–
DNA and OX–DNA adducts, respectively, throughout this work. Other than the differences
in carrier ligand, the adducts formed by CP, CBDCA, and OX appear to be identical in terms
of the type of adduct formed (60–65% intrastrand GG, 25–30% intrastrand AG, 5–10%
intrastrand GNG, and 1–3% interstrand) and the site of adduct formation (5-7).
Because of their abundance, the intrastrand GG adducts are thought to be major
determinants of the cytotoxic response to platinum anticancer agents. The basis for the
differences in tumor range and mutagenicity of OX compared to CP and CBDCA is not
known but is thought to be determined by the ability of proteins involved in damage
recognition, damage repair, and/or damage tolerance to discriminate between CP and OX
adducts. For example, hMSH2 and MutS bind with greater affinity to CP–GG adducts than
to OX–GG adducts (8, 9), and as might be expected from this difference in binding affinity,
defects in mismatch repair result in resistance to CP and CBDCA, but not to OX (8, 10-13).
Similarly, a number of damage recognition proteins and transcription factors, especially
those with HMG domains, have been shown to discriminate between CP– and OX–GG
adducts (14, 15). The mechanism(s) by which the binding of these proteins to Pt–DNA
adducts influences the cytotoxic response is not known but has been postulated to involve
shielding of the adducts from DNA repair and tolerance mechanisms (16-19), activation of
signaling pathways leading to cell cycle arrest or apoptosis, and/or hijacking of transcription
factors needed for DNA replication or cell division (15, 20). The binding specificity has
been determined for only a few of these proteins, but where it has been studied, these
proteins bind to CP–GG adducts with higher affinity than to OX–GG adducts (14, 15, 21).
Finally, translesion DNA polymerases such as pol β and pol η have been shown to bypass
OX–GG adducts with higher efficiency than CP–GG adducts (19, 22, 23), which might
contribute to the differences in CP and OX mutagenicity.
The CP– and OX–GG adducts form in the major groove and have been shown to bend the
DNA in the direction of the major groove (24-28). The proteins that discriminate between
CP– and OX–GG adducts either bind to bent DNA or bend the DNA in the direction of the
major groove after binding (29-32). Because these proteins primarily interact with the minor
groove, we have hypothesized that the ability of the proteins to discriminate between CP–
and OX–GG adducts probably results from subtle differences in conformation or
conformational dynamics in the DNA containing the two adducts rather than from physical
interaction of the proteins with the carrier ligands of the adducts in the major groove (26). A
number of structures have been reported for CP–GG and OX–GG adducts (24, 25, 27, 33,
34). The overall conformation of DNA containing these adducts appears to be similar, but
exact comparisons have been difficult to make because the structures have been determined
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by different techniques (crystallography vs NMR), in different sequence contexts, and with
oligonucleotides that differ in length. Further, the NMR structures obtained to date have
varied with respect to the number and resolution of NMR constraints obtained and the
molecular mechanics simulations used to convert the NMR constraints to final structures
(24-26). X-ray crystallographic structures have been reported for the CP–GG and OX–GG
adducts in the TGGT sequence context (27, 28), but differences between the solution and X-
ray structures (26) of the OX–GG DNA adduct suggest that the X-ray structures may have
been at least partially constrained by crystal packing restraints (26). CP–GG adducts appear
to be more mutagenic in the AGG sequence context than in the CGG, TGG, or GGG
sequence context (35-38). In addition, our previous studies with translesion DNA
polymerases have utilized DNA templates with oxaliplatin located in the AGGC sequence
context (19, 22, 23, 39). Thus, we have recently obtained a high-resolution NMR solution
structure of the OX–GG adduct in the mutagenic AGGC sequence context (the underlined
bases indicate the position of the OX–GG adduct) (26).
In this paper, we report high-resolution NMR solution structures of the CP–GG adduct and
undamaged DNA in the same sequence context. Moreover, the solution structures were
determined using the same experimental approach employed for the OX–GG adduct. This is
the first direct comparison of the CP–GG adduct, the OX–GG adduct, and undamaged DNA
solution structures in the same sequence context. This study has allowed us to resolve the
effects of sequence context and platinum carrier ligand on several previously reported
chemical shift anomalies. For example, we find that several unusual chemical shifts,
previously reported for the OX–GG adduct compared to earlier NMR solution structures of
CP–GG adducts, were also seen for the CP–GG adduct in the AGGC sequence context.
Thus, these chemical shift differences appear to reflect the effect of sequence context rather
than the presence of the trans-(R,R)-1,2-diaminocyclohexane carrier ligand. The direct
comparison of NOESY data from the CP–GG adduct, the OX–GG adduct, and undamaged
DNA in the same sequence context has also allowed us to more accurately determine the
effect of CP–GG and OX–GG adducts on NOE cross-peak volumes of nearby DNA
residues. For example, we have been able to show that the unusually weak cross-peak
between H2′ of the C complementary to the 5′ G and H6/ H8 of the base complementary to
the 5′ flanking residue reported by Marzilli et al. (25) is a feature of CP–GG adducts, but
not of OX–GG adducts. Finally, the direct comparison of CP–GG and OX–GG solution
structures has allowed us to identify several conformational differences not seen in the
crystallographic comparison of the two adducts in the TGGT sequence context. For
example, significant differences were observed between the two adducts: buckle at the 5′
G6•C19 base pair, opening at the 3′ G7•C18 base pair, twist at the A5G6•T20C19 base pair
step, slide, twist, and roll at the G6G7•C19C18 base pair step, slide at the G7C8•C18G17
base pair step, G6G7 dihedral angle, and overall bend angle. These subtle conformational
differences may allow differential recognition of CP– and OX–GG adducts by critical DNA
binding proteins that influence the cytotoxic response to these adducts.
MATERIALS AND METHODS
Preparation and HPLC Purification of the CP–GG Oligonucleotide
The GG strand (the strand containing the Pt–GG adduct) and complement (CC strand) were
purchased from Operon Biotechnologies, Inc. The GG strand containing the cisplatin adduct
was prepared using our previously described procedure (26). The DNA duplex (Figure 1)
was prepared by adding the CC strand solution to the GG strand in NMR buffer [100 mM
NaCl and 5 mM phosphate buffer (pH 7.0)] at a calculated 1:1 ratio. The DNA was annealed
by cooling overnight from 70 °C to room temperature. The 1:1 ratio of CC strand to GG
strand was verified by analysis of two-dimensional (2D) DQF-COSY NMR spectra as
described previously (26).
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Characterization of the CP–GG Adduct by Liquid Chromatography and Mass Spectroscopy
(LC–MS)
LC–MS characterizations of the CP–GG adduct and undamaged DNA in the AGGC
sequence context were performed following the procedure reported previously, with slight
modifications (26). The platinated and undamaged 12-mer GG strand were first separated by
HPLC. Following desalting and concentration, the purity of the CP-adducted 12-mer GG
strand was confirmed by denaturing gel electrophoresis. No unplatinated 12-mer GG strand
was detected by this method, indicating that the CP-adducted 12-mer GG strand was >95%
pure (data not shown). The CP[d(GpG)] adduct and undamaged DNA digests were analyzed
on a Surveyor LC system, connected to Surveyor photodiode array (PDA) and LCQDECA
ion trap mass spectrometer (Thermo Finnigan, San Jose, CA). A Clarity 3 μm Oligo-RP
column (100 mm × 4.60 mm) (Phenomenex, Torrance, CA) was operated with a linear
gradient from 100% 10 mM ammonium acetate (pH 3.5) to 80% MeOH in 10 mM
ammonium acetate for 20 min at a flow rate of 200 μL/min. UV spectra (λ = 200–400 nm)
were recorded with a Finnigan Surveyor PDA detector, and positive and negative full scan
(m/z 80–1000) mass spectra were acquired with Xcalibur (Thermo Finnigan).
NMR Experiments
Two NMR samples were prepared for both the undamaged DNA and CP–GG DNA adduct,
one in 5% D2O/95% H2O buffer (H2O sample) for detection of exchangeable protons and
the other in 100% D2O buffer (D2O sample) for detection of nonexchangeable protons. All
NMR spectra were acquired on a Varian Inova 600 or 800 MHz spectrometer. The carrier
frequency for protons was set on the H2O signal. One-dimensional (1D) proton spectra were
recorded at temperatures ranging from 2 to 40 °C for detection of exchangeable protons.
NOESY spectra were recorded at 800 MHz using a mixing time of 200 ms, 32 transients,
and 320 or 400 complex FIDs corresponding to spectral widths of 20 and 9 ppm in both
dimensions for the samples in H2O and D2O, respectively. WATERGATE was employed to
suppress the water peak in water samples. Distance constraints were obtained from the 200
ms NOESY spectra in both H2O and D2O (40). The assignments were obtained initially
from NOE connectivities and confirmed by analysis of 2D DQF-COSY (41) (2048 × 720
complex points, 9 ppm spectral width in both dimensions, 32 transients) and TOCSY data
(2048 × 320 complex points, 9 ppm spectral width in both dimensions, 32 transients). 2D
DQF-COSY data were also used to extract J coupling constraints for determination of sugar
pucker. 2D 1H–31P HETCOR (42) (heteronuclear correlation spectroscopy) data were
collected for the D2O samples (800 × 112 complex points, spectral width of 2040 × 900 Hz,
320 transients) at 600 MHz. The 1H and 31P chemical shifts were referenced relative to
internal TSP and external 10% (w/v) trimethyl phosphate at 0.0 ppm, respectively. NMR
data were processed with NMRPipe and analyzed with Felix (version 2000; Molecular
Simulations, Inc., San Diego, CA).
Structure Calculations
The structure of the DNA duplexes was calculated using CNS (Crystallographic and NMR
System) version 1.1 with a simulated annealing protocol (43). To construct the CP
intrastrand platinum cross-link between G6 and G7, two new residues (XGU and YGU)
were added to the topology and parameter database of CNS. Residue YGU was modified for
G6 by adding a bond between the N7 atom of G6 and the Pt atom of NH3-Pt. XGU was
modified for G7 by combining the Pt(NH3)2 moiety with N7 of the G7 residue. The new
bonds, angles, dihedral angles, and force constants were obtained from ref 44. An initial
extended structure was produced from the duplex sequence. Two types of constraints were
used in the structure calculations: experimentally derived and halonomic distance
constraints. A total of 551 and 920 NOE-derived distance restraints were employed in the
structure calculations for CP–GG DNA and undamaged DNA, respectively. The NOE cross-
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peaks were standardized to the Cyt H5–H6 cross-peaks, with a H5–H6 distance of 2.5 Å.
One additional angstrom was added for distance constraints involving methyl groups.
Planarity was also restrained for all base pairs (45) with the exception of the base pairs
associated with the CP adduct, where the force constant was reduced by half. Although the
sugar pucker conformation was estimated from analysis of NOE constraints and simulations
of cross-peaks in DQF-COSY spectra to encompass both A and B DNA conformations, a
broad range of torsion angle restraints were employed for the sugar–phosphate torsion
angles, i.e., α (−70 ± 50°), β (180 ± 50°), γ (60 ± 35°), ζ (−85 ± 50°), χ (−120 ± 50°), δ
(120 ± 50°), and ε (180 ± 50°) in the structure calculations. Finally, six distance restraints
per base pair were employed to describe Watson–Crick base pairing (45). The lower and
upper bounds for H-bond distance constraints were set to 7%. However, for base pairs
associated with the CP adduct, the bounds were increased to 10%. Of 20 calculated
structures, the 15 with the lowest energy were accepted as a family.
RESULTS AND DISCUSSION
Characterization of the Cisplatin–GG Intrastrand Cross–Link
The purity of the CP-adducted GG strand was >95% as determined by HPLC and denaturing
gel electrophoresis (see Materials and Methods). Following hybridization with the
complementary strand, the CP–GG 12-mer duplex was further characterized following the
same procedure reported by Wu et al. (26) for the OX–GG 12-mer duplex. Both undamaged
12-mer duplex and 12-mer duplex containing the CP–GG intrastrand cross-link were
digested to the deoxynucleoside and CP[d(GpG)] level, respectively, with a combination of
deoxyribonuclease I, nuclease P1, and alkaline phosphatase as described by Eastman (46)
and were characterized by HPLC–UV–MS. Using this procedure, the Pt–GG intrastrand
cross-link is digested to Pt[d(GpG)], the Pt–AG intrastrand cross-link to Pt[d(ApG)], and the
Pt–G monoadduct to Pt(dG). In addition, both the GNG intrastrand cross-link and the GG
interstrand cross-link are digested to dG–Pt–dG (46). The HPLC–UV chromatogram of the
digestion products derived from the undamaged 12-mer duplex exhibited four peaks (Figure
2, I). These peaks were identified as dC, dT, dG, and dA on the basis of their retention time,
UV spectrum, and mass spectra (data not shown) that were identical to those of authentic
standards (data not shown). The relative abundance of the individual deoxynucleosides was
as expected for the 12-mer duplex. The 12-mer duplex containing the CP–GG intrastrand
cross-link showed the four normal deoxynucleosides and one additional peak eluting just
before dG (Figure 2, IIA). This additional digestion product had the same retention time and
UV spectrum as the synthetic CP[d(GpG)] standard (data not shown). This additional peak
was further identified as CP[d(GpG)] by the presence of the expected molecular ions in both
the positive (m/z 824.89) (Figure 2, IIB) and negative (m/z 822.90) (data not shown) modes.
In addition, the presence of a peak with a mass of 806.98 (positive m/z 808.01 and negative
m/z 805.93) corresponds to the molecular weight of CP[d(GpG)] after dissociation of an
ammonia molecule of cisplatin (Figure 2, IIB). Last, the MS spectra also showed the
expected Pt isotopes, confirming the presence of a Pt compound. No digestion products were
detected with the masses and isotopic pattern expected for the dG–CP–dG, CP[d(ApG)], or
CP(dG) adducts (data not shown). These data demonstrate that the 12-mer duplex employed
in this NMR study consisted exclusively of the CP–GG intrastrand cross-link. The lack of
any detectable CP–AG intrastrand cross-link is consistent with previous reports that the Pt–
AG diadduct comprises less than 3% of the total Pt intrastrand cross-links formed in the
AGG sequence context (26, 47).
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Chemical shift assignments for both the CP and undamaged DNA samples were obtained as
described previously for the OX–GG adduct in the same 12-mer duplex (26). Assignments
of the nonexchangeable base and sugar protons were obtained by analysis of NOESY
spectra recorded in D2O buffer at 25 °C. For example, the NOESY region for the CP–DNA
duplex in Figure 3 shows NOE correlations between the base (purine H8/pyrimidine H6)
and the H1′ sugar protons and between the base (purine H8/pyrimidine H6) and the H2′ and
H2″ sugar protons. Sequential connectivities can be observed without interruptions from C1
to C12 in the GG strand and from G13 to G24 in the CC strand. Comparable data for the
undamaged DNA are shown in Figure S1 of the Supporting Information. Once sequential
assignments were obtained for H8/H6, H1′, H2′, and H2″, the assignments of the other
(H3′, H4′, H5′, and H5″) sugar protons were extended on the basis of the NOESY, DQF-
COSY, and TOCSY spectra, following standard procedures (41). Assignments of the
exchangeable protons were obtained by analyzing distance connectivities between the imino
and base/amino proton regions of NOESY spectra in H2O buffer at 2 °C. The chemical shift
assignments for the CP–DNA duplex and undamaged DNA are listed in Tables S1 and S2 of
the Supporting Information, respectively.
Previous NMR studies of Pt–GG adducts have examined a single type of adduct (CP or OX)
in a single sequence context and have compared both the proton chemical shifts and NOE
cross-peak intensities with average values for undamaged B-DNA in a variety of sequence
contexts (24, 25, 27, 33) (34). However, it is unclear whether some of the observed
differences are due to differences in sequence context rather than between the platinated and
unplatinated strand. We are in a unique position to directly determine the effect of Pt–GG
adducts on both the proton chemical shifts and NOE cross-peak intensities of the DNA in
the region of the Pt–GG adduct, as our NMR data were collected on OX–GG DNA (26),
CP–GG DNA, and undamaged B-DNA in the same AGGC sequence context. Chemical shift
differences among OX–GG DNA, CP–GG DNA, and undamaged B-DNA for the H6/H8,
H1′, H2′, and H2″ protons are shown in Figure 4. It is clear from this comparison that the
formation of Pt–GG adducts primarily affects chemical shifts of protons within the central 4
bp region. Moreover, a larger difference in chemical shifts is observed for protons on the
strand containing the adduct relative to the complementary strand. Both the CP–GG and
OX–GG adducts exhibited downfield chemical shifts for the H8 proton of both G6 and G7,
the H6 proton of C8, and the H1′ protons of A5, G6, and C8. In contrast, upfield chemical
shifts were observed for the H1′ proton of G7, the H2′ proton of G6 and G7, and the H2″
proton of G7.
Previous studies have not made direct comparisons of platinated adducts with undamaged
DNA in the same sequence context and thus were unable to determine the effect of Pt–DNA
adducts on proton chemical shifts with this precision. However, downfield chemical shifts
have been reported for the H8 protons of the 5′ and 3′ G residues for all Pt–GG adducts
studied to date (24-26, 33), so this has been considered a universal feature of Pt–GG
adducts. In their analysis of a CP–GG adduct, Marzilli et al. (25) reported a much greater
downfield chemical shift for the H8 proton on the 5′ G residue than for the 3′ G residue and
a significant upfield shift of the H2′ proton on the C complementary to the 5′ G residue,
which they considered universal features of all CP–GG adducts. However, we do not
observe either of these features in direct comparisons of the CP–GG DNA (Table S1)
adducts with undamaged DNA (Table S2), so these chemical shifts do not appear to be
features of all CP–GG adducts. Our adducts differ from all previous adducts in that they are
in the AGGC sequence context, so the differences in proton chemical shifts between our Pt–
GG adducts and the CP–GG adduct reported by Marzilli et al. (25) may reflect an effect of
sequence context (AGGC vs CGGC). Experiments are currently underway to clarify the
effect of sequence context on NMR data and conformation of the Pt–GG adducts.
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With respect to NOE cross-peaks (Table S3 of the Supporting Information) for both CP–GG
and OX–GG adducts, we observed stronger G6 H8–G7 H8 NOE cross-peaks and weaker A5
H1′–G6 H8 and G6 H1′–G7 H8 cross-peaks compared to those in undamaged DNA,
consistent with data reported previously for other CP–GG adducts. We also see some
significant difference in NOE cross-peak intensities between CP–GG and OX–GG adducts.
Marzilli et al. (25) had previously suggested that an unusually weak NOE cross-peak
between H2′ of the C complementary to the 5′ G residue and H6/H8 of the base
complementary to the 5′ flanking base was a universal feature of all CP–GG adducts. Here,
we find that the C19 H2′–T20 H6 NOE cross-peak for the CP–GG adduct in the AGGC
sequence context is also weaker than that in undamaged DNA (Table S3). In contrast, we
have previously reported (26) that the NOE cross-peak between C19 H2′ and T20 H6 for
the OX–GG adduct was near normal. In addition, compared to the OX–DNA adduct, the
CP–DNA adduct exhibited a stronger G6 H1′–G7 H8 NOE cross-peak and a weaker G6
H8–G7 H8 NOE cross-peak (Table S3). These differences in NOE cross-peak intensity are
consistent with the differences in DNA helical parameters of CP– and OX–DNA adducts,
such as the differences observed for the twist in the A5 T20•G6 C19 base pair step and twist
and roll in the G6 C19•G7 C18 base pair step (see below).
The CP–GG and OX–GG adducts also differ significantly from each other in that the extent
of the downfield chemical shift for the G7 H8 and G6 H1′ protons and the upfield chemical
shift of the A5 and G6 H2′ protons was significantly greater for the CP–GG adduct than the
OX–GG adduct (Figure 4). The difference in the chemical shift of the G7 H8 proton is
particularly interesting because it could theoretically arise from a difference in the canting of
the 3′ G residue in relation to the 5′ G residue for the OX–GG and CP–GG adducts. The
degree of base canting for both the 5′ and 3′ G residues was determined by measuring the
C5–N7–Pt–cis N and C8–N7–Pt–cis N dihedral angles (48) (Table S4 of the Supporting
Information). However, no significant differences were observed in these dihedral angles for
the OX–GG and CP–GG adducts. It is likely that the differences in G7 H8 chemical shifts
between the OX–GG and CP–GG adducts result from the anisotropic effects of the (NH3)2Pt
and 1,2-diaminocyclohexane-Pt moieties, since sequence context and buffer conditions were
identical.
Temperature Dependence of Imino–Solvent Exchange
The temperature dependence of the imino proton resonances associated with the duplexes
(Figure 5) was monitored by 1D 1H NMR in H2O buffer solution [100 mM NaCl and 5 mM
Na2HPO4/NaH2PO4 (pH 7.0)] at temperatures ranging from 2 to 40 °C. For both CP–DNA
and OX–DNA duplexes, the imino peaks of G6 and G7 totally disappear while other imino
peaks survive at 40 °C, indicating that the binding of both CP and OX results in enhanced
solvent accessibility of the G6 and G7 guanines. These data are consistent with previous
reports for other Pt–GG intrastrand cross-links (24). Moreover, for both CP and OX, the
imino peak for G6 shows a greater loss of intensity at 25 °C relative to the imino peak for
G7, suggesting that the exchange rate for the G6 imino proton is faster than for the G7 imino
proton. These observations are consistent with previous reports for other Pt–GG adducts (24,
25, 33) and suggest that both the CP and OX adducts may be more distorted and/or flexible
on the 5′ side of the adduct than on the 3′ side.
Assignment of31 P Resonances
Phosphorus chemical shifts are influenced strongly by backbone torsion angles. To
investigate the effects of the CP–GG adduct on the phosphodiester backbone conformation,
2D 1H–31P HETCOR spectra were recorded for both the CP–DNA duplex and undamaged
DNA (Figure S2A,B of the Supporting Information). Phosphorus signals were assigned from
the H3′(i)–P(i) and P(i)–H4′(i+1) cross-peaks with the chemical shifts of the phosphorus
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atoms listed in Tables S1 and S2. All backbone phosphate resonances of the CP–GG 12-mer
duplex were dispersed between −3.41 and −4.50 ppm over a range of 1.09 ppm. This is only
slightly larger than the range (−3.80 to −4.40 ppm) observed for the phosphodiester
backbone in undamaged B-DNA. Marzilli et al. (25) reported that for their CP–GG adduct
the 31P signal for the phosphate group between the two G residues coordinated to platinum
was significantly shifted downfield (to −3.08 ppm). However, we find almost no difference
in the chemical shift of the 31P signal among the CP–DNA duplex (Table S1), the OX–DNA
duplex (26), and undamaged DNA (Table S2). These data indicate that the formation of a
CP– or OX–GG adduct in the AGGC sequence context does not significantly perturb the
DNA backbone.
J Coupling Constants and Sugar Pucker Estimates
Figure 6 shows an expanded portion of the H1′–H2′ and H1′–H2″ region of the DQF–
COSY spectra for the undamaged DNA and CP–DNA duplex at 25 °C in D2O with the A5,
G6, and G7 cross-peaks indicated by the dotted lines. The relative intensity of the H1′–H2″
and H1′–H2′ DQF–COSY cross-peak reflects the relative size of the coupling between
these sugar protons and can be used to provide information about sugar conformation (25,
49). Sugars with a C2′-endo (S) conformation give fairly weak H1′–H2″ and strong H1′–
H2′ DQF–COSY cross-peaks, while sugars with near-C3′-endo (N) conformations give the
opposite relative intensity pattern. To obtain sugar pucker for both the CP–DNA duplex and
undamaged DNA, the procedure reported previously for the OX–DNA adduct was used
(26). J coupling constants were obtained by simulating DQF-COSY cross-peaks using
Chords version 2.0. Tables S5 and S6 of the Supporting Information list the J coupling
constants obtained for all residues except terminal residues for the CP–DNA duplex and
undamaged DNA, respectively. The sums of the H1′ J coupling constants, Σ1′, were used to
calculate fractions of south (C2′-endo), fs, conformers for each sugar residue by assuming a
two-state dynamic equilibrium and using the equation
where Σ1′ = JH1′−H2′ + JH1′−H2″.
Table 1 summarizes the assigned sugar pucker (×c4s) for undamaged DNA, the CP–GG
adduct, and the OX–GG adduct. For the undamaged DNA, all sugar puckers have the S
conformation, including A5, G6, and G7. In contrast, for the OX–GG adduct, the G6 sugar
pucker was found to be mostly N and the A5 sugar pucker primarily S, but with some N
characteristics (26). For the CP–GG adduct, both the A5 and G6 sugar puckers are
intermediate between S and N. The other residues have primarily the S sugar pucker,
characteristic of B-DNA. These data are consistent with previous reports (24, 25) and
indicate that compared to undamaged DNA, platinated DNA adducts exhibit distortion only
in the sugar rings for the 5′ G residue and the base 5′ to the G.
Structure Calculations
We obtained 551 and 920 experimental distance constraints for the CP–DNA duplex and
undamaged DNA, respectively, from the 200 ms NOESY spectra in both H2O and D2O.
These experimental distance constraints were then used as input for CNS to calculate the
respective solution structures of the CP–DNA duplex and undamaged DNA. Additional
constraints included base pair constraints between heavy atoms involved in hydrogen
bonding and a planarity constraint to keep the base pairs in a plane (45). Force constants and
charges for CP bound to the two G residues were obtained as described in Materials and
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Methods. The structural parameter statistics for the CP–DNA duplex and undamaged DNA
are listed in Table 2. Of 20 calculated structures for each DNA, the 15 with the lowest
energy were accepted as a family. The rmsd for the superimposition of the non-H atoms for
all 15 final structures was 0.81 Å for the CP–DNA duplex and 1.21 for undamaged DNA,
which indicates good convergence for both structures. The fact that there were no distance
and dihedral angle restraint violations >0.5 Å and 5°, respectively, indicated that the final
structures satisfied the imposed experimental restraints. The stereoviews of the average
solution structures obtained for the CP–DNA duplex and undamaged DNA are shown in
Figure 7.
Accuracy of the Structures
To verify the accuracy of the structures, theoretical NOESY spectra were back-calculated
from the average final structure and known chemical shifts using the Model module and the
matrix-doubling capability (MSI) of Felix. The accuracy of the computed structure can be
judged by comparing the back-calculated NOEs with the experimental 2D NOE data. The
comparison of experimental and back-calculated NOEs for the entire molecule is shown in
Figures S3 and S4 of the Supporting Information for undamaged DNA and the CP–DNA
duplex, respectively. Experimental cross-peak volumes were compared to their theoretical
counterparts to compute R-factors:
in which Rc is the crystallographic-equivalent R-factor, Rx is the sixth-root residual index,
and Ie and It are the experimental and theoretical cross-peak volumes for the ith cross-peak,
respectively. R-Factors were computed for the NOESY experiments (mixing time of 300
ms). For undamaged DNA, Rc and Rx values of the average structure were 0.21 and 0.04,
respectively. For the CP–DNA duplex, Rc and Rx values of the average structure were 0.16
and 0.04, respectively. The obtained R-factors indicate that the structures are in good
agreement with the measured NOEs.
Comparison with CP–DNA and OX–DNA Conformations
We are able to directly compare the solution structures of the CP–GG and OX–GG (26)
adducts in the AGGC sequence context, since the DNA sequences are identical and the
NMR data and structural calculations were performed in the same manner as our previous
structural study of the OX–GG adduct (26). The platinum geometry is compared in Table S7
of the Supporting Information. However, as the location of the platinum atom is not
determined by NMR constraints, the significance of these observations is unclear. An
overlay of the central 4 bp of the CP–DNA duplex with undamaged DNA and with the OX–
DNA duplex (26) is shown in Figure 7, and selected DNA helical parameters are compared
in Table 3. The CP–GG and OX–GG adducts differ significantly in terms of twist at the A5-
G6 base pair step, slide, twist, and roll at the G6-G7 base pair step, slide at the G7-C8 base
pair step, buckle for the G6•C19 base pair, opening for the G7•C18 base pair, G6-G 7
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dihedral angle, and overall bend. One or more of these conformational differences may be
important for the differential recognition of CP–GG and OX–GG adducts by some mismatch
repair proteins, DNA binding proteins (including certain transcription factors), and DNA
polymerases. For example, the HMG domain of HMG-B1 has been shown to bind with
higher efficiency to CP–GG adducts than to OX–GG adducts (14), and a crystal structure of
the HMG–CP–DNA complex has been reported (31). The DNA helical parameters for the
HMG–CP–DNA complex have been included in Table 3 for comparison. Many of the DNA
helical parameters for the DNA–adduct complex differ from those of the solution structures
of both the CP–GG and OX–GG adducts, which probably reflects the severe DNA distortion
imposed by binding of the HMG protein. However, the twist at the A5-G6 and G6-G7 base
pair steps and slide at the G7-C8 base pair steps for the HMG–CP–GG DNA complex are
much closer to those of the CP–GG solution structure than the OX–GG solution structure. If
any of these conformations are characteristic of the protein–DNA conformation in the initial
recognition step, this may facilitate recognition of the CP–GG adduct by the HMG domain.
The conformational difference at the G7-C8 base pair step might be particularly critical
because both the affinity of the HMG domain for the CP–GG adduct (14, 50, 51) and the
ability of the HMG domain to discriminate between CP–GG and OX–GG adducts (14) are
highly dependent on the base to the 3′ side of the adduct. There are, of course, a number of
important limitations inherent in this type of comparison. First, we are comparing a crystal
structure of the HMG–CP–GG DNA complex with the solution structures of the CP–GG and
OX–GG DNA adducts. Second, it is likely that the final, stable protein–DNA complex has a
conformation different from that of the initial protein–DNA recognition complex. Third, the
sequence context of the CP–GG adduct in the HMG–CP–GG complex differs from that in
the CP–GG and OX–GG solution structures. Hence, experiments are underway to determine
solution NMR structures of CP–GG and OX–GG adducts in complex with an HMG domain
from one or more proteins that discriminate between these adducts, in the same AGGC
sequence context, to better characterize conformational differences that are important for
differential protein recognition of the adducts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Duplex DNA sequence used in this study. The underlined bases show the position of the
platinum adduct. Chemical structures of cisplatin and oxaliplatin.
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HPLC–UV–MS chromatogram of digestion products obtained from an undamaged 12-mer
duplex (I) and from the same 12-mer duplex containing the CP–GG intrastrand cross-link.
The spectra include (I) the HPLC–UV elution profile of the digestion products obtained
from the undamaged 12-mer duplex, (II)A the HPLC–UV elution profile of the digestion
products obtained from the 12-mer duplex containing the CP–GG adduct [the peak with the
asterisk corresponds to the elution position of a CP–d(GpG) standard], and (II)B MS-
positive mass spectrum of the peak identified with the asterisk in Figure 2(II)A.
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Expanded nonexchangeable proton regions taken from the 2D NOESY (200 ms) spectrum
acquired in D2O for the CP–GG 12-mer duplex. The H6/H8–H2′/H2″ (top) and H6/H8–
H1′ (bottom) regions are shown. The left and right regions correspond to the GG (the strand
containing the Pt–GG adduct) and CC (complementary) strands, respectively.
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Effect of platination on chemical shifts of selected base and sugar proton chemical shifts.
The values were determined by using experimental chemical shifts (Tables S1 and S2 and
ref 26).
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Expanded imino region from 1D 1H NMR spectra of the CP–DNA (top) and OX–DNA
(bottom) (26) duplexes recorded in H2O buffer at various temperatures. The positions of the
nucleotides in the 12-mer duplexes that give rise to the resonances are indicated. The
asterisk in the 1D 1H NMR spectra of the CP–DNA adduct indicates the terminal guanine
(G24). The experimental temperatures are shown at the left.
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Expanded region of the DQF-COSY spectra showing the H1′–H2′ and H1′–H2″ cross-
peaks of the undamaged DNA and CP–DNA duplex at 25 °C in H2O. Assigned peaks are
labeled.
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(A) Stereoviews of the average solution structures of the CP–DNA duplex (left) and
undamaged DNA (right) in the AGGC sequence context. The platinum atom in the CP–
DNA adduct is shown as a yellow sphere. (B) Comparison of the central 4 bp of the CP–
DNA adduct (green) with those of the undamaged DNA (blue) and OX–DNA adduct (red)
(26).
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Table 1
Percent South Conformation (fs) Derived from Quantitative Simulation of DQF-COSY Data Obtained for
Undamaged DNA and CP–DNA and OX–DNA Adducts in the AGGC Sequence Context
residue undamaged CP–DNA OX–DNA
C1 0.86 0.93
C2 0.93 0.89 0.91
T3 0.97 0.92 0.98
C4 0.88 0.86 0.93
A5 0.85 0.62 0.72
G6 0.83 0.63 0.32
G7 0.86 0.95 0.88
C8 0.66 0.71
C9 0.95 0.73 0.63




G14 0.83 0.81 0.93
A15 0.90 0.83 0.88
G16 0.95 0.86
G17 0.95 0.95 0.88
C18 0.93 0.80 0.73
C19 0.85 0.80 0.71
T20 0.95 0.80 0.88
G21 0.78 0.95 0.90
A22 0.86 0.88 0.84
G23
G24 0.97
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Table 2
Structural Statistics for CP–DNA and Undamaged DNA Structuresa
structure-related information CP–DNA undamaged DNA





Number of Empirical Constraints
hydrogen bonds 72 72
backbone dihedral angles 168 168
Structural Statistics
distance violation per structure (>0.5 Å) 0 1
dihedral angle violations per structure (>5°) 0 0
rmsd from ideal covalent geometry
bond lengths (Å) 0.01 ± 0.00 0.01 ± 0.01
bond angles (deg) 0.66 ± 0.03 0.78 ± 0.03
dihedral angles (deg) 0.00 ± 0.00 0.00 ± 0.00
Structure Quantity
rmsd from the mean structure
 within the family (Å)
  all atoms 0.92 ± 0.30 1.37 ± 0.30
  non-H atoms 0.81 ± 0.26 1.21 ± 0.30
a
Of 20 calculated structures, the 15 with the lowest energy are accepted as a family.
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Table 3
Comparison of Selected 3-DNA and MADBEND Parameters for Undamaged DNA, CP–GG DNA, OX–GG
DNA (26), and DNA from the HMG–CP–GG DNA Complex (31)
undamaged CP–DNA OX–DNA HMG–CP–DNA
A5•T20/G6•C19
 shift (Å) 0.44 ± 0.05 −0.04 ± 0.10 0.17 ± 0.04 1.17
 slide (Å) 0.09 ± 0.08 −0.65 ± 0.10 −0.89 ± 0.10 1.32
 twist (deg) 27.81 ± 0.58 35.3 ± 1.40 22.1 ± 1.30 31.7
G6•C19/G7•C18
 shift (Å) 0.24 ± 0.05 0.99 ± 0.08 0.84 ± 0.14 −0.78
 slide (Å) −1.55 ± 0.08 −0.55 ± 0.10 −1.36 ± 0.30 −1.66
 twist (deg) 30.29 ± 0.58 18.40 ± 1.40 25.20 ± 2.00 19.20
 roll (deg) 1.12 ± 0.74 36.30 ± 3.20 28.30 ± 3.20 57.20
G7•C18/C8•G17
 shift (Å) 0.24 ± 0.05 −0.99 ± 0.17 −1.24 ± 0.1 −0.45
 slide (Å) −1.55 ± 0.08 −0.33 ± 0.13 0.93 ± 0.10 0.08
G6•C19
 buckle (deg) 10.39 ± 0.31 4.20 ± 2.20 12.60 ± 2.40 29.00
G7•C18
 buckle (deg) −0.90 ± 0.31 −4.58 ± 1.67 −3.18 ± 1.70 −11.80
 opening (deg) 0.83 ± 0.24 −1.24 ± 0.93 5.73 ± 0.53 −5.20
G6G7 dihedral angle 42.70 ± 3.10 35.60 ± 2.80
 overall bend (deg) (MADBEND) 22 ± 10 31 ± 10
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